House Republicans are poised to open a two-front war on ObamaCare, pushing for a vote this weekend on a bill that would delay the health care law in exchange for raising the debt ceiling -- a week after handing the Senate a separate bill that would defund the law.
House Republicans are poised to open a two-front war on ObamaCare, pushing for a vote this weekend on a bill that would delay the health care law in exchange for raising the debt ceiling -- a week after handing the Senate a separate bill that would defund the law.
A senior House source told Fox News that the tentative plan is to debate and vote on the emerging debt-ceiling bill on Saturday. That bill is expected to cover a lot of ground, with provisions to raise the debt ceiling, tee up future tax reform, approve the Keystone pipeline and, perhaps most important to Republicans, delay ObamaCare by one year.
This comes as the Senate deals with a measure that would keep the government open past Sept. 30 in exchange for defunding the health law. The Senate voted Wednesday to advance the bill and, if Democrats can clear one final hurdle on Friday, Majority Leader Harry Reid plans to strip out the ObamaCare measure and send it back to the House.
Read the full story here: http://fxn.ws/19C30Fy
Source: F
Semaglutide Shows Promise for MASH Resolution, Severe Fibrosis: Naim Alkhouri, MD
May 9th 2025Naim Alkhouri, MD, spoke to the potential for glucagon-like peptide-1 (GLP-1) receptor agonists to transform the treatment landscape for patients with metabolic dysfunction-associated steatohepatitis (MASH) and severe fibrosis.
Read More
New Research Challenges Assumptions About Hospital-Physician Integration, Medicare Patient Mix
April 22nd 2025On this episode of Managed Care Cast, Brady Post, PhD, lead author of a study published in the April 2025 issue of The American Journal of Managed Care®, challenges the claim that hospital-employed physicians serve a more complex patient mix.
Listen
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen